These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30869416)

  • 21. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC; Hauser RA
    Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa in the treatment of Parkinson's disease.
    Schapira AH; Emre M; Jenner P; Poewe W
    Eur J Neurol; 2009 Sep; 16(9):982-9. PubMed ID: 19538218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.
    Poewe W; Mahlknecht P
    Neurol Clin; 2020 May; 38(2):255-267. PubMed ID: 32279709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
    Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
    Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
    Di Luca DG; Reyes NGD; Fox SH
    Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.
    You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC
    Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
    Wright BA; Waters CH
    Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.